KTTA
Pasithea Therapeutics Corp. [KTTA] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
KTTA Stock Summary
Top 10 Correlated Stocks
KTTA
In the News
KTTA Financial details
Company Rating
-
Market Cap
7.78M
Income
-287.56M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
8
Optionable
No
Shortable
Yes
Earnings
12 May 2024
P/E
-0.61
Forward P/E
-
PEG
-0
P/S
30.04
P/B
6.15
P/C
-
P/FCF
-0.46
Quick Ratio
9.63
Current Ratio
10.16
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-221.65
EPS next Y
-
EPS next Q
-
EPS this Y
25.82%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
68.99%
-
-
-
-
SMA20
16.67%
SMA50
-41.67%
SMA100
-59.08%
Inst Own
-
Inst Trans
-
ROA
-934%
ROE
-787%
ROC
-0.56%
Gross Margin
99%
Oper. Margin
-6610%
Profit Margin
-118986%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
5.26-17.4
52W High
-91.59%
52W Low
-71.4%
RSI
54.56
Rel Volume
28.92
Avg Volume
6.31K
Volume
182.44K
Perf Week
31.19%
Perf Month
20.17%
Perf Quarter
-64.6%
Perf Half Y
-67.43%
-
-
-
-
Beta
0.884
-
-
Volatility
0.12%, 0.13%
Prev Close
3.62%
Price
1.43
Change
-0.69%
Company Profile
- Volume Average 6.31K
- Market Capitalization 7.78M
- Employee 8
- CEO Dr. Tiago Reis Marques M.D., Ph.D.
- Headquarters Miami Beach,FL,US
- IPO Date 2021-09-15
-
Website
https://www.pasithea.com 
Pasithea Therapeutics Corp., a biotechnology company, engages in research and discovery of treatments for psychiatric and neurological disorders. It also intends to operate anti-depression clinics and provide business support services using trained pharmacists to administer intravenous infusions of ketamine. The company was incorporated in 2020 and is headquartered in Miami Beach, Florida.
